Compare Orchid Chemicals with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs IPCA LABS - Comparison Results

ORCHID PHARMA LTD     Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD IPCA LABS ORCHID PHARMA LTD/
IPCA LABS
 
P/E (TTM) x -0.5 23.1 - View Chart
P/BV x 0.1 4.5 2.6% View Chart
Dividend Yield % 0.0 0.1 -  

Financials

 ORCHID PHARMA LTD   IPCA LABS
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
IPCA LABS
Mar-18
ORCHID PHARMA LTD/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs194695 27.9%   
Low Rs35400 8.8%   
Sales per share (Unadj.) Rs276.5260.2 106.3%  
Earnings per share (Unadj.) Rs-79.219.0 -417.5%  
Cash flow per share (Unadj.) Rs-43.533.1 -131.5%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs53.9213.0 25.3%  
Shares outstanding (eoy) m70.45126.20 55.8%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.42.1 19.7%   
Avg P/E ratio x-1.428.9 -5.0%  
P/CF ratio (eoy) x-2.616.6 -15.9%  
Price / Book Value ratio x2.12.6 82.6%  
Dividend payout %05.3 0.0%   
Avg Mkt Cap Rs m8,06769,120 11.7%   
No. of employees `0002.813.3 21.1%   
Total wages/salary Rs m2,5277,359 34.3%   
Avg. sales/employee Rs Th6,956.12,477.4 280.8%   
Avg. wages/employee Rs Th902.5555.2 162.6%   
Avg. net profit/employee Rs Th-1,993.0180.6 -1,103.3%   
INCOME DATA
Net Sales Rs m19,47732,836 59.3%  
Other income Rs m407418 97.4%   
Total revenues Rs m19,88433,254 59.8%   
Gross profit Rs m1,1034,505 24.5%  
Depreciation Rs m2,5191,777 141.7%   
Interest Rs m5,227240 2,176.0%   
Profit before tax Rs m-6,2362,905 -214.6%   
Minority Interest Rs m200-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-125511 -24.5%   
Profit after tax Rs m-5,5802,394 -233.1%  
Gross profit margin %5.713.7 41.3%  
Effective tax rate %2.017.6 11.4%   
Net profit margin %-28.77.3 -392.9%  
BALANCE SHEET DATA
Current assets Rs m11,01419,455 56.6%   
Current liabilities Rs m32,06010,076 318.2%   
Net working cap to sales %-108.128.6 -378.3%  
Current ratio x0.31.9 17.8%  
Inventory Days Days9598 96.9%  
Debtors Days Days3467 50.1%  
Net fixed assets Rs m29,44020,260 145.3%   
Share capital Rs m705252 279.1%   
"Free" reserves Rs m2,04326,633 7.7%   
Net worth Rs m3,80026,886 14.1%   
Long term debt Rs m9,0182,340 385.4%   
Total assets Rs m46,51041,173 113.0%  
Interest coverage x-0.213.1 -1.5%   
Debt to equity ratio x2.40.1 2,726.6%  
Sales to assets ratio x0.40.8 52.5%   
Return on assets %-0.86.4 -11.9%  
Return on equity %-146.98.9 -1,649.1%  
Return on capital %-3.710.8 -34.7%  
Exports to sales %37.947.6 79.5%   
Imports to sales %22.614.9 152.1%   
Exports (fob) Rs m7,37815,642 47.2%   
Imports (cif) Rs m4,4064,884 90.2%   
Fx inflow Rs m7,51315,642 48.0%   
Fx outflow Rs m5,6494,884 115.7%   
Net fx Rs m1,86510,759 17.3%   
CASH FLOW
From Operations Rs m1,6823,411 49.3%  
From Investments Rs m-9,860-1,354 728.2%  
From Financial Activity Rs m6,644-1,304 -509.5%  
Net Cashflow Rs m-1,535753 -203.8%  

Share Holding

Indian Promoters % 32.3 45.9 70.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.6 11.4 40.4%  
FIIs % 3.3 25.3 13.0%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 17.4 317.8%  
Shareholders   84,811 36,892 229.9%  
Pledged promoter(s) holding % 54.9 2.1 2,566.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   PANACEA BIOTECH  DISHMAN PHARMA  J.B.CHEMICALS  NATCO PHARMA  DIVIS LABORATORIES  

Compare ORCHID PHARMA LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY19); Net Profit Up 51.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, IPCA LABS has posted a net profit of Rs 2 bn (up 51.7% YoY). Sales on the other hand came in at Rs 9 bn (up 10.3% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

ORCHID PHARMA LTD Announces Quarterly Results (2QFY19); Net Profit Up 67.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended September 2018, ORCHID PHARMA LTD has posted a net profit of Rs 231 m (up 67.1% YoY). Sales on the other hand came in at Rs 1 bn (down 31.9% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY19); Net Profit Up 24.1% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, IPCA LABS has posted a net profit of Rs 1 bn (up 24.1% YoY). Sales on the other hand came in at Rs 10 bn (up 15.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Jul 24, 2019 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD 8-QTR ANALYSIS

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS